Jiří Vencovský

37.4k total citations · 4 hit papers
267 papers, 12.6k citations indexed

About

Jiří Vencovský is a scholar working on Rheumatology, Epidemiology and Immunology. According to data from OpenAlex, Jiří Vencovský has authored 267 papers receiving a total of 12.6k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Rheumatology, 103 papers in Epidemiology and 82 papers in Immunology. Recurrent topics in Jiří Vencovský's work include Inflammatory Myopathies and Dermatomyositis (99 papers), Rheumatoid Arthritis Research and Therapies (80 papers) and Systemic Sclerosis and Related Diseases (36 papers). Jiří Vencovský is often cited by papers focused on Inflammatory Myopathies and Dermatomyositis (99 papers), Rheumatoid Arthritis Research and Therapies (80 papers) and Systemic Sclerosis and Related Diseases (36 papers). Jiří Vencovský collaborates with scholars based in Czechia, United Kingdom and United States. Jiří Vencovský's co-authors include Ladislav Šenolt, Karel Pavelká, Michal Tomčík, Martin Komarc, Maja Špiritović, Hana Štorkánová, Sabína Oreská, Barbora Heřmánková, Radim Bečvář and Kristýna Bubová and has published in prestigious journals such as The Lancet, PLoS ONE and The Journal of Physiology.

In The Last Decade

Jiří Vencovský

253 papers receiving 12.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study

2021 4.1k citations Hana Štorkánová, Sabína Oreská et al. profile →
The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation

2016 689 citations Jiří Vencovský et al. profile →
119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands

2004 668 citations Ernest Choy, Ingrid E. Lundberg et al. profile →
Idiopathic inflammatory myopathies

2021 347 citations Ingrid E. Lundberg, Jiří Vencovský et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Jiří Vencovský	4.1k	3.6k	2.8k	2.4k	932	267	12.6k
Xuan Zhang	3.1k 0.8×	2.5k 0.7×	5.1k 1.8×	7.9k 3.2×	758 0.8×	868	22.7k
James A. Koziol	1.8k 0.4×	2.2k 0.6×	1.5k 0.5×	2.5k 1.0×	1.5k 1.6×	270	14.0k
Young Ho Lee	4.8k 1.2×	1.8k 0.5×	4.3k 1.5×	4.3k 1.8×	1.4k 1.4×	1.0k	19.6k
Zhihong Liu	2.5k 0.6×	1.7k 0.5×	2.7k 1.0×	7.2k 2.9×	1.5k 1.6×	1.3k	25.1k
William H. Robinson	6.3k 1.5×	6.2k 1.7×	5.4k 1.9×	6.4k 2.6×	1.2k 1.3×	621	25.1k
Hiroshi Hashimoto	6.4k 1.6×	1.6k 0.4×	3.9k 1.4×	4.9k 2.0×	693 0.7×	865	22.9k
John D. Isaacs	6.1k 1.5×	907 0.3×	6.0k 2.1×	2.4k 1.0×	2.4k 2.5×	395	16.4k
James R. Stone	1.9k 0.5×	2.4k 0.7×	1.0k 0.4×	4.8k 1.9×	230 0.2×	348	14.0k
Karel Pavelká	10.8k 2.6×	1.1k 0.3×	3.7k 1.3×	2.6k 1.1×	3.7k 4.0×	374	19.7k
Kazuhiko Yamamoto	6.8k 1.7×	1.5k 0.4×	8.7k 3.1×	5.5k 2.3×	2.3k 2.4×	772	25.1k

Countries citing papers authored by Jiří Vencovský

Since Specialization

Citations

This map shows the geographic impact of Jiří Vencovský's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiří Vencovský with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiří Vencovský more than expected).

Fields of papers citing papers by Jiří Vencovský

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiří Vencovský. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiří Vencovský. The network helps show where Jiří Vencovský may publish in the future.

Co-authorship network of co-authors of Jiří Vencovský

This figure shows the co-authorship network connecting the top 25 collaborators of Jiří Vencovský. A scholar is included among the top collaborators of Jiří Vencovský based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiří Vencovský. Jiří Vencovský is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aggarwal, Rohit, Joachim Schessl, Zsuzsanna Bata‐Csörgõ, et al.. (2025). Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub-analysis of the ProDERM Study. Rheumatology and Therapy. 12(5). 855–871.

Charles‐Schoeman, Christina, Jon T. Giles, Nancy E. Lane, et al.. (2024). Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years. Rheumatology and Therapy. 11(1). 157–175. 5 indexed citations

Vencovský, Jiří, et al.. (2024). Drug survival analysis of etanercept compared with monoclonal antibody tumour necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a propensity score-matched analysis from the Czech ATTRA registry. Scandinavian Journal of Rheumatology. 54(2). 79–86.

Stibůrková, Blanka, Kateřina Pavelcová, Monika Beličková, et al.. (2023). Novel Somatic UBA1 Variant in a Patient With VEXAS Syndrome. Arthritis & Rheumatology. 75(7). 1285–1290. 33 indexed citations

Oreská, Sabína, Hana Štorkánová, Jaroslav Kudlička, et al.. (2023). Cardiovascular risk in myositis patients compared with the general population. Lara D. Veeken. 63(3). 715–724. 9 indexed citations

Štorkánová, Hana, Thuong Trinh‐Minh, Hana Hulejová, et al.. (2023). S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin. Lara D. Veeken. 63(3). 817–825. 6 indexed citations

Heřmánková, Barbora, Maja Špiritović, Sabína Oreská, et al.. (2023). Effect of an 8-Week Tailored Physiotherapy Program on Sexual Health in Women with Scleroderma and Myositis: A Controlled Pilot Study. Rheumatology and Therapy. 10(4). 1089–1105. 1 indexed citations

Štorkánová, Hana, Maja Špiritović, Sabína Oreská, et al.. (2022). Hsp90 as a Myokine: Its Association with Systemic Inflammation after Exercise Interventions in Patients with Myositis and Healthy Subjects. International Journal of Molecular Sciences. 23(19). 11451–11451. 6 indexed citations

Heřmánková, Barbora, Maja Špiritović, Sabína Oreská, et al.. (2021). Sexual function in patients with idiopathic inflammatory myopathies: a cross-sectional study. Lara D. Veeken. 60(11). 5060–5072. 8 indexed citations

10.

Špiritović, Maja, Barbora Heřmánková, Sabína Oreská, et al.. (2021). The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up. Arthritis Research & Therapy. 23(1). 173–173. 16 indexed citations

11.

Mann, H., Olga Kryštůfková, Josef Zámečnı́k, et al.. (2020). Interleukin-35 in idiopathic inflammatory myopathies. Cytokine. 137. 155350–155350. 5 indexed citations

12.

Betteridge, Zoë, Hector Chinoy, Jiří Vencovský, et al.. (2019). Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis. Lara D. Veeken. 59(5). 1026–1030. 13 indexed citations

13.

Burmester, Gerd R, Iain B. McInnes, Joel M. Kremer, et al.. (2018). Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody. Arthritis & Rheumatology. 70(5). 679–689. 62 indexed citations

14.

Ramsköld, Daniel, Olga Kryštůfková, H. Mann, et al.. (2018). Effect of CTLA4‐Ig (abatacept) treatment on T cells and B cells in peripheral blood of patients with polymyositis and dermatomyositis. Scandinavian Journal of Immunology. 89(1). e12732–e12732. 12 indexed citations

15.

Weinblatt, Michael E., Iain B. McInnes, Joel M. Kremer, et al.. (2017). A Randomized Phase II b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. Arthritis & Rheumatology. 70(1). 49–59. 72 indexed citations

16.

Hulejová, Hana, Jakub Závada, Petra Hánová, et al.. (2017). Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. PLoS ONE. 12(8). e0183420–e0183420. 28 indexed citations

17.

Tansley, Sarah, Zoë Betteridge, Harsha Gunawardena, et al.. (2012). Clinical Differences Between Adult and Juvenile Dermatomyositis Associated with Anti-NXP2 Autoantibodies.. UCL Discovery (University College London). 1 indexed citations

18.

Allen, Elizabeth, Patrick Kiely, RG Cooper, et al.. (2005). Inter-rater reliability and validity of two disease activity assessment tools in patients with idiopathic inflammatory myositis (IIM). UCL Discovery (University College London). 1 indexed citations

19.

Özen, Seza, Mehmet Alikaşifoğlu, Ayşı̇n Bakkaloğlu, et al.. (2002). Tumour necrosis factor α G→A −238 and G→A −308 polymorphisms in juvenile idiopathic arthritis. Lara D. Veeken. 41(2). 223–227. 68 indexed citations

20.

Isenberg, David, Eliezer M. Van Allen, RG Cooper, et al.. (2002). Development of disease activity and damage indices for myositis: Further testing of four tools in adult onset patients.. UCL Discovery (University College London). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact